We are live on ! Find out more
APTO

Aptose Biosciences

Delisted

APTO was delisted on the 1st of April, 2025.

56 hedge funds and large institutions have $174M invested in Aptose Biosciences in 2019 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

540% more capital inflows, than outflows

Capital inflows: $56.8M | Capital outflows: $8.88M

278% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 9

81% more funds holding

Funds holding: 31 → 56 (+25)

57% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 7

54% more call options, than puts

Call options by funds: $1.41M | Put options by funds: $918K

15.88% more ownership

Funds ownership: 25.62% → 41.5% (+16%)

Holders
56
Holders Change
+25
Holders Change %
+80.65%
% of All Funds
1.1%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.06%
New
34
Increased
11
Reduced
7
Closed
9
Calls
$1.41​M
Puts
$918​K
Net Calls
+$496​K
Net Calls Change
+$745​K

APTO Hedge Fund Activity: Q4 2019 in Review

56 of the 5,095 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences (APTO) for Q4 2019, worth a combined $174M — up 489% from $29.6M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new APTO positions and 9 closed out — a net gain of 25 holders — while 11 added to existing stakes and 7 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $13.8M. The largest seller was Point72 Asset Management, cutting an estimated $4.14M.

  • 56 institutional investors held Aptose Biosciences (APTO) as of Q4 2019, up from 31 in Q3 2019.
  • Funds reported $174M of Aptose Biosciences stock for Q4 2019, up 489% quarter-over-quarter.
  • 34 funds opened new Aptose Biosciences positions in Q4 2019 and 9 closed out, a net change of +25 holders.
  • The largest Aptose Biosciences buyer in Q4 2019 was Consonance Capital Management, an estimated $13.8M added.
  • The largest Aptose Biosciences seller in Q4 2019 was Point72 Asset Management, an estimated $4.14M sold.

Based on aggregated 13F filings for Q4 2019.